Videos

Laura Blair explains why streamlining the patient journey via and simpler tools help ensure adherence from the point of prescription.

Laura Blair discusses what makes enrollment friction, and how the right balance of AI and human support can improve hub utilization and speed to therapy.

Laura Blair discusses how DTP models make manufacturers rethink traditional access and distribution strategies.

Emily Gallo explains how end-to-end visibility and data integration transform pharma supply chains from reactive cost centers into resilient assets.

Cindy Baksh, ConnectiveRx, discusses pharma's shift from reactive audits to real-time prevention—protecting billions in copay spend while ensuring support reaches the patients who need it most.

Emily Gallo, SVP of OptiFreight® Logistics at Cardinal Health, discusses how predictive analytics and actionable benchmarking bridge the data-to-decision gap in pharma logistics.

Michael Oleksiw says loneliness and behavior gaps drive prescription drop-offs, making early, personalized support critical to adherence.

Traci Miller, senior director of Access and Patient Support at Cardinal Health Sonexus, explains how hub data helps pharma companies shift from reactive firefighting to proactive access optimization.

Pleio CEO Michael Oleksiw discusses how loneliness can affect GLP-1 patient adherence.

Digital tools are improving efficiency, but human engagement remains critical for patient support.

Corey Ford explains why the rise of biosimilars and specialty therapies requires a shift from universal support models to highly tailored strategies.

Nareda Mills explains why patient services teams are more than support, but strategic drivers for brands.

Tina Valbh explains how disengagement and patient abandonment reveal gaps in support programs.

Pharma can optimize DTP strategies by leveraging data on affordability and patient behavior.

Corey Ford, principal at Nuvera, explains how pharma is shifting focus from HCPs to patients in support programs and commercialization.

Nareda Mills, global president of Patient Solutions at Inizio Engage, discusses how patient services are measured and which metrics demonstrate value to leadership.

Workflow alignment, e-prescribing integration, and behavior change strategies are critical to reducing friction across the direct-to-patient ecosystem.

Matt Sample breaks down the operational hurdles and strategies for transitioning to the FDA’s new 12-digit NDC format.

From KPI clarity to right-sized staffing, Kimberly Howard explains how to measure true FRM impact and build flexible models that adapt to market realities.

Brok Vandersteen explains how life sciences companies can strategically adopt DTP models for better patient access and commercial success.

Kristine McGaughey, vice president of Implementation at ConnectiveRx, shares her insights on timing, strategy, and planning to ensure a smooth therapy launch.

Kimberly Howard, senior manager of Field Reimbursement Services at CoverMyMeds, explains how aligning hubs and reimbursement teams improves patient support.

Tina Valbh, managing partner at PharmaKonnect and co-founder of Tina’s Warriors, discusses the biggest post therapy launch patient support gaps.

Jordan Armstrong, VP of Business Development at AssistRX, explains how companies can tailor direct-to-patient strategies into their commercialization plans.

In the first part of his Pharmaceutical Commerce interview, Jay Bregman, founder and CEO of Andel, discusses how employers are exploring direct-to-employer drug purchasing models that bypass traditional pathways.

Valerie Bandy and Ryan Rotar, both from Tecsys, examine how hospital pharmacy leaders are reshaping their expectations and prioritizing value-driven partnerships over traditional transactional vendor relationships. They explore the growing shift toward self-distribution and direct purchasing, as well as how transparency and proactive communication are now essential to mitigating logistics risk and safeguarding patient care. This interview stresses technology’s role as a critical enabler of data visibility, empowering manufacturers to build long-term trust through consistent performance and shared accountability.

In the final part of his Pharma Commerce video interview, John Stanford, Incubate’s executive director, argues that while Medicare price controls may reduce federal spending, they have yet to meaningfully improve patient access—contending that true reform must address insurance design, out-of-pocket costs, and the long-term impact on life sciences innovation and investment.

In the third part of his Pharma Commerce video interview, John Stanford, Incubate’s executive director, shares how Incubate’s analysis of SEC filings reports dozens of halted research programs following the Inflation Reduction Act’s passage, while recent legislative changes tied to orphan drugs appear to be influencing renewed rare disease investment.